MedTrace Logo

Vancomycin for Primary Sclerosing Cholangitis

NCT03710122 · Status: TERMINATED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 102

Last updated 2026-04-22

Study results available
· View outcomes & findings →

Summary

To find out if vancomycin is a safe and effective therapy for primary sclerosing cholangitis.

Funding Source - FDA OOPD

Conditions

  • Primary Sclerosing Cholangitis

Interventions

DRUG

Vancomycin

Firvanq by Azurity Pharmaceuticals, Inc.

OTHER

Placebo

Placebo for Vancomycin

Sponsors & Collaborators

  • Arizona State University

    collaborator OTHER

  • Elizabeth Carey

    lead OTHER

Principal Investigators

  • Elizabeth Carey, MD · Mayo Clinic

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
76 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-23
Primary Completion
2025-03-03
Completion
2025-03-20
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03710122 on ClinicalTrials.gov